New results show promise in treatment of SOD1-ALS

lesturnerClinical Trials, Foundation Blog, Home Page, Research News

New results from the Phase 3 clinical trial of tofersen, a drug in development by Biogen, have shown promise in treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). According to the 12-month data, earlier initiation of treatment with …